Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 125

1.

PARP inhibition as a prototype for synthetic lethal screens.

Liu X.

Methods Mol Biol. 2013;986:123-37. doi: 10.1007/978-1-62703-311-4_9. Review.

PMID:
23436410
2.

Inducing synthetic lethality using PARP inhibitors.

Boss DS, Beijnen JH, Schellens JH.

Curr Clin Pharmacol. 2010 Aug;5(3):192-5. Review.

PMID:
20406170
3.

Targeted therapy for cancer using PARP inhibitors.

Lord CJ, Ashworth A.

Curr Opin Pharmacol. 2008 Aug;8(4):363-9. doi: 10.1016/j.coph.2008.06.016. Review.

PMID:
18644251
4.

Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations.

Dedes KJ, Wilkerson PM, Wetterskog D, Weigelt B, Ashworth A, Reis-Filho JS.

Cell Cycle. 2011 Apr 15;10(8):1192-9. Epub 2011 Apr 15.

5.

The emerging role of poly(ADP-Ribose) polymerase inhibitors in cancer treatment.

Sandhu SK, Yap TA, de Bono JS.

Curr Drug Targets. 2011 Dec;12(14):2034-44. Review.

PMID:
21777194
6.

[Cancer therapy by PARP inhibitors].

Seimiya H.

Nihon Rinsho. 2015 Aug;73(8):1330-5. Review. Japanese.

PMID:
26281686
7.

Poly(ADP-ribose) polymerase inhibitors in cancer treatment: a clinical perspective.

Sandhu SK, Yap TA, de Bono JS.

Eur J Cancer. 2010 Jan;46(1):9-20. doi: 10.1016/j.ejca.2009.10.021. Epub . Review.

PMID:
19926276
8.

PARP inhibitors: mechanism of action and their potential role in the prevention and treatment of cancer.

Basu B, Sandhu SK, de Bono JS.

Drugs. 2012 Aug 20;72(12):1579-90. doi: 10.2165/11635510-000000000-00000. Review.

PMID:
22834679
9.

Molecular pathways: how can BRCA-mutated tumors become resistant to PARP inhibitors?

Bouwman P, Jonkers J.

Clin Cancer Res. 2014 Feb 1;20(3):540-7. doi: 10.1158/1078-0432.CCR-13-0225. Epub 2013 Nov 22. Review.

10.

PARP inhibition induces BAX/BAK-independent synthetic lethality of BRCA1-deficient non-small cell lung cancer.

Paul I, Savage KI, Blayney JK, Lamers E, Gately K, Kerr K, Sheaff M, Arthur K, Richard DJ, Hamilton PW, James JA, O'Byrne KJ, Harkin DP, Quinn JE, Fennell DA.

J Pathol. 2011 Aug;224(4):564-74. doi: 10.1002/path.2925. Epub 2011 Jun 27.

PMID:
21706479
11.

Enhancement of synthetic lethality via combinations of ABT-888, a PARP inhibitor, and carboplatin in vitro and in vivo using BRCA1 and BRCA2 isogenic models.

Clark CC, Weitzel JN, O'Connor TR.

Mol Cancer Ther. 2012 Sep;11(9):1948-58. doi: 10.1158/1535-7163.MCT-11-0597. Epub 2012 Jul 9.

12.

Triple-negative breast cancer and poly(ADP-ribose) polymerase inhibitors.

Park Y, Moriyama A, Kitahara T, Yoshida Y, Urita T, Kato R.

Anticancer Agents Med Chem. 2012 Jul;12(6):672-7. Review.

PMID:
22263793
13.

Poly(ADP-ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic.

Yap TA, Sandhu SK, Carden CP, de Bono JS.

CA Cancer J Clin. 2011 Jan-Feb;61(1):31-49. doi: 10.3322/caac.20095. Epub 2011 Jan 4. Review.

14.

Role of PARP inhibitors in cancer biology and therapy.

Davar D, Beumer JH, Hamieh L, Tawbi H.

Curr Med Chem. 2012;19(23):3907-21. Review.

15.

A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair.

Ashworth A.

J Clin Oncol. 2008 Aug 1;26(22):3785-90. doi: 10.1200/JCO.2008.16.0812. Epub 2008 Jun 30. Review.

PMID:
18591545
16.

Poly(ADP-ribosyl)ation polymerases: mechanism and new target of anticancer therapy.

Heitz F, Harter P, Ewald-Riegler N, Papsdorf M, Kommoss S, du Bois A.

Expert Rev Anticancer Ther. 2010 Jul;10(7):1125-36. doi: 10.1586/era.10.53. Review.

PMID:
20645701
17.

Making the best of PARP inhibitors in ovarian cancer.

Banerjee S, Kaye SB, Ashworth A.

Nat Rev Clin Oncol. 2010 Sep;7(9):508-19. doi: 10.1038/nrclinonc.2010.116. Epub 2010 Aug 10. Review.

PMID:
20700108
18.

PARP inhibitors in cancer therapy: two modes of attack on the cancer cell widening the clinical applications.

Drew Y, Plummer R.

Drug Resist Updat. 2009 Dec;12(6):153-6. doi: 10.1016/j.drup.2009.10.001. Epub 2009 Nov 25. Review.

PMID:
19939726
19.

Development of PARP inhibitors in oncology.

Rodon J, Iniesta MD, Papadopoulos K.

Expert Opin Investig Drugs. 2009 Jan;18(1):31-43. doi: 10.1517/13543780802525324 . Review.

PMID:
19053880
20.

Synthetic lethal approaches to breast cancer therapy.

Rehman FL, Lord CJ, Ashworth A.

Nat Rev Clin Oncol. 2010 Dec;7(12):718-24. doi: 10.1038/nrclinonc.2010.172. Epub 2010 Oct 19. Review.

PMID:
20956981
Items per page

Supplemental Content

Write to the Help Desk